This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $45.96, marking a +1.23% move from the previous day.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $44.59, marking a +0.16% move from the previous day.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $43.92, moving +1.64% from the previous trading session.
Philip Morris (PM) Cuts 2021 Earnings View on Currency Impacts
by Zacks Equity Research
Philip Morris (PM) trims its 2021 adjusted earnings forecast to reflect volatility in currency rates. It expects higher currency impacts in 2021 than mentioned earlier.
Altria (MO) Benefits From Pricing, Oral Tobacco Expansion
by Zacks Equity Research
Altria (MO) strives to expand on! amid consumers' rising preference for low-risk tobacco alternatives. Moreover, strong pricing for tobacco products bodes well.
Is Altria Group (MO) a Great Stock for Value Investors?
by Zacks Equity Research
Is Altria Group (MO) a great pick from the value investor's perspective right now? Read on to know more.
Here's How Post Holdings (POST) is Placed Before Q4 Earnings
by Zacks Equity Research
Post Holdings' (POST) fourth-quarter performance is likely to have benefited from recovery in foodservice revenues and growth in BellRing Brands.
Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVY
Altria (MO) Q3 Earnings Miss Estimates, Revenues Down Y/Y
by Zacks Equity Research
Altria's (MO) third-quarter performance is affected by lower shipment volumes in the smokeable and oral tobacco categories. Nevertheless, higher pricing in these categories is an advantage.
Altria (MO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of -3.17% and -4.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Factors to Consider Before Altria Group's (MO) Q3 Earnings
by Zacks Equity Research
Altria Group's (MO) third-quarter results are likely to reflect gains from pricing and strength in reduced risk products.
Altria (MO) Stock Moves -0.02%: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $48.22, marking a -0.02% move from the previous day.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Altria (MO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Altria (MO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should WisdomTree U.S. Dividend exFinancials ETF (DTN) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DTN
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
Is WisdomTree U.S. Dividend exFinancials ETF (DTN) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTN
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $48.13 in the latest trading session, marking a -1.17% move from the prior day.
Philip Morris' (PM) IQOS, Beyond Nicotine Growth Plans On-Track
by Zacks Equity Research
Philip Morris (PM) benefits from the growing market for IQOS devices globally. It is also focused on the expansion of Beyond Nicotine products to support inhaled therapeutics.
Focus on Low-Risk Offerings Drives Altria (MO), Pricing Aids
by Zacks Equity Research
Altria (MO) strives to expand IQOS and on! amid consumers' rising preference on low-risk tobacco alternatives. Moreover, strong pricing for tobacco products is driving revenues.
Altria (MO) Stock Moves -0.04%: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $46.71, marking a -0.04% move from the previous day.
Zacks Industry Outlook Highlights: Philip Morris, Altria Group and Turning Point Brands
by Zacks Equity Research
Zacks Industry Outlook Highlights: Philip Morris, Altria Group and Turning Point Brands
3 Tobacco Stocks to Watch Out For on RRPs and Pricing Gains
by Vidya Nair
The Zacks Tobacco industry gains from reduced-risk products and solid pricing. Such upsides have been benefiting companies like Philip Morris (PM), Altria (MO) and Turning Point Brands (TPB). However, regulatory headwinds in cigarettes are a concern.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $46.50 in the latest trading session, marking a +1.4% move from the prior day.